BE897251A - Compositions pharmaceutiques antihypertensive synergetique - Google Patents
Compositions pharmaceutiques antihypertensive synergetique Download PDFInfo
- Publication number
- BE897251A BE897251A BE0/211143A BE211143A BE897251A BE 897251 A BE897251 A BE 897251A BE 0/211143 A BE0/211143 A BE 0/211143A BE 211143 A BE211143 A BE 211143A BE 897251 A BE897251 A BE 897251A
- Authority
- BE
- Belgium
- Prior art keywords
- sep
- indapamide
- pharmaceutical composition
- tert
- compounds
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 9
- 230000003276 anti-hypertensive effect Effects 0.000 title description 3
- 230000002195 synergetic effect Effects 0.000 title description 3
- NDDAHWYSQHTHNT-UHFFFAOYSA-N indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229960004569 indapamide Drugs 0.000 claims abstract description 16
- 150000001875 compounds Chemical class 0.000 claims abstract description 14
- 150000003839 salts Chemical class 0.000 claims abstract description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 4
- 230000003287 optical effect Effects 0.000 claims abstract description 3
- 239000000203 mixture Substances 0.000 abstract description 5
- HTWFXPCUFWKXOP-UHFFFAOYSA-N Tertatalol Chemical compound C1CCSC2=C1C=CC=C2OCC(O)CNC(C)(C)C HTWFXPCUFWKXOP-UHFFFAOYSA-N 0.000 abstract description 4
- 239000000470 constituent Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 11
- 102000030621 adenylate cyclase Human genes 0.000 description 8
- 108060000200 adenylate cyclase Proteins 0.000 description 8
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 6
- 229940095074 cyclic amp Drugs 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 4
- 241000272201 Columbiformes Species 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 2
- -1 3-tert-butylamino-2-hydroxypropoxy Chemical group 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000002876 beta blocker Substances 0.000 description 2
- 229940097320 beta blocking agent Drugs 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229940039009 isoproterenol Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000011775 sodium fluoride Substances 0.000 description 2
- 235000013024 sodium fluoride Nutrition 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- WPWNEKFMGCWNPR-UHFFFAOYSA-N 3,4-dihydro-2h-thiochromene Chemical compound C1=CC=C2CCCSC2=C1 WPWNEKFMGCWNPR-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000037849 arterial hypertension Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000003617 erythrocyte membrane Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000009454 functional inhibition Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000003975 mesenteric artery Anatomy 0.000 description 1
- 230000022082 negative regulation of vasoconstriction Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229950007002 phosphocreatine Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8212058A FR2529785A1 (fr) | 1982-07-09 | 1982-07-09 | Composition pharmaceutique a base d'indapamide et de 8-(3-tertbutylamino 2-hydroxypropoxy)-thiachromanne |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE897251A true BE897251A (fr) | 1984-01-09 |
Family
ID=9275835
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE0/211143A BE897251A (fr) | 1982-07-09 | 1983-07-08 | Compositions pharmaceutiques antihypertensive synergetique |
Country Status (16)
| Country | Link |
|---|---|
| JP (1) | JPS5927813A (OSRAM) |
| AU (1) | AU557601B2 (OSRAM) |
| BE (1) | BE897251A (OSRAM) |
| CA (1) | CA1197191A (OSRAM) |
| CH (1) | CH655007A5 (OSRAM) |
| DE (1) | DE3324785C2 (OSRAM) |
| FR (1) | FR2529785A1 (OSRAM) |
| GB (1) | GB2123293B (OSRAM) |
| IE (1) | IE55364B1 (OSRAM) |
| IT (1) | IT1173729B (OSRAM) |
| LU (1) | LU84902A1 (OSRAM) |
| NL (1) | NL8302435A (OSRAM) |
| NZ (1) | NZ204849A (OSRAM) |
| OA (1) | OA07489A (OSRAM) |
| SE (1) | SE8303886L (OSRAM) |
| ZA (1) | ZA834978B (OSRAM) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL8600137A (nl) * | 1985-02-05 | 1986-09-01 | Sandoz Ag | Farmaceutische preparaten die desgewenst met een diureticum gecombineerde 3-aminopropoxyindolen bevatten, alsmede werkwijzen voor het toepassen van deze preparaten. |
| PL193976B1 (pl) * | 2002-07-01 | 2007-04-30 | Pliva Krakow | Tabletka o przedłużonym działaniu zawierająca indapamid i sposób wytwarzania tabletki o przedłużonym działaniu zawierającej indapamid |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1203691A (en) * | 1968-03-06 | 1970-09-03 | Science Union & Cie | New disubstituted n-amino indoline derivatives and process for preparing them |
| GB1308191A (en) * | 1970-04-06 | 1973-02-21 | Science Union & Cie | Thiochroman derivatives and a process for preparing them |
| DE2227423A1 (de) * | 1971-06-15 | 1972-12-21 | Ciba-Geigy Ag, Basel (Schweiz) | Neue pharmazeutische Präparate |
-
1982
- 1982-07-09 FR FR8212058A patent/FR2529785A1/fr active Granted
-
1983
- 1983-07-06 LU LU84902A patent/LU84902A1/fr unknown
- 1983-07-07 SE SE8303886A patent/SE8303886L/xx not_active Application Discontinuation
- 1983-07-07 IT IT48641/83A patent/IT1173729B/it active
- 1983-07-07 ZA ZA834978A patent/ZA834978B/xx unknown
- 1983-07-08 GB GB08318512A patent/GB2123293B/en not_active Expired
- 1983-07-08 JP JP58124582A patent/JPS5927813A/ja active Granted
- 1983-07-08 DE DE3324785A patent/DE3324785C2/de not_active Expired
- 1983-07-08 CH CH3786/83A patent/CH655007A5/fr not_active IP Right Cessation
- 1983-07-08 NL NL8302435A patent/NL8302435A/nl not_active Application Discontinuation
- 1983-07-08 CA CA000432068A patent/CA1197191A/fr not_active Expired
- 1983-07-08 NZ NZ204849A patent/NZ204849A/en unknown
- 1983-07-08 AU AU16702/83A patent/AU557601B2/en not_active Ceased
- 1983-07-08 OA OA58056A patent/OA07489A/xx unknown
- 1983-07-08 BE BE0/211143A patent/BE897251A/fr not_active IP Right Cessation
- 1983-07-08 IE IE1597/83A patent/IE55364B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IE831597L (en) | 1984-01-09 |
| FR2529785A1 (fr) | 1984-01-13 |
| AU557601B2 (en) | 1986-12-24 |
| SE8303886D0 (sv) | 1983-07-07 |
| JPS5927813A (ja) | 1984-02-14 |
| DE3324785C2 (de) | 1986-10-09 |
| ZA834978B (en) | 1984-03-28 |
| CH655007A5 (fr) | 1986-03-27 |
| FR2529785B1 (OSRAM) | 1984-12-07 |
| LU84902A1 (fr) | 1984-03-22 |
| IE55364B1 (en) | 1990-08-29 |
| CA1197191A (fr) | 1985-11-26 |
| NZ204849A (en) | 1986-04-11 |
| DE3324785A1 (de) | 1984-01-12 |
| SE8303886L (sv) | 1984-01-10 |
| JPH0250084B2 (OSRAM) | 1990-11-01 |
| OA07489A (fr) | 1985-03-31 |
| NL8302435A (nl) | 1984-02-01 |
| GB2123293A (en) | 1984-02-01 |
| AU1670283A (en) | 1984-01-12 |
| GB2123293B (en) | 1985-10-09 |
| IT8348641A0 (it) | 1983-07-07 |
| IT1173729B (it) | 1987-06-24 |
| GB8318512D0 (en) | 1983-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mladěnka et al. | Comprehensive review of cardiovascular toxicity of drugs and related agents | |
| Cannon et al. | Effect of alpha-methyl DOPA in severe and malignant hypertension | |
| WO2001043747A1 (fr) | Comprime matriciel permettant la liberation prolongee de trimetazidine apres administration par voie orale | |
| RU2125448C1 (ru) | Фармацевтическая композиция и способ ее получения, способ лечения нарушений, развивающихся вследствие нейродегенеративных процессов | |
| FR2735365A1 (fr) | Utilisation d'un antagoniste de l'angiotensine ii et d'un derive du benzofurane pour la preparation d'un medicament utile dans le traitement des affections cardiovasculaires | |
| BE897251A (fr) | Compositions pharmaceutiques antihypertensive synergetique | |
| US4469690A (en) | Synergistic compositions of renal dopaminergic agent and β-blocker | |
| EP0966282B1 (en) | Use of the angiotensin ii antagonists losartan and exp-3174 to treat symptomatic heart failure | |
| US4451465A (en) | Anti-obesity agents | |
| CA1238576A (en) | Synergistic pharmaceutical composition | |
| Uyama et al. | The effect of a thromboxane synthetase inhibitor, OKY-046, on urinary excretion of immunoreactive thromboxane B2 and 6-keto-prostaglandin F1 alpha in patients with ischemic cerebrovascular disease. | |
| Snider et al. | Is dopamine a neurohormone of the adrenal medulla? Studies with morphine stimulation | |
| EP1115399B1 (fr) | Utilisation d'une composition pharmaceutique contenant, en association, un antagoniste des recepteurs at1 de l'angiotensine ii et l'indomethacine pour la fabrication d'un medicament pour traiter les glomerulonephrites chroniques | |
| US6121328A (en) | Racemic propranolol | |
| FR2641971A1 (fr) | Composition pharmaceutique antihypertensive associant le benazepril et un diuretique thiazidique | |
| Rahmani | Vascular smooth muscle, endothelial regulation and effects of aspirin in hypertension | |
| EP2026796B1 (fr) | Utilisation d'un inhibiteur de vasopeptidase pour le traitement de l'hypertension arterielle pulmonaire | |
| Sandberg et al. | The Appearance Of PF1 And PF3 In Activated Human Platelets | |
| Walker et al. | Catecholamine modulatory effects of nepicastat (RS-25560-197), a novel, potent and selective inhibitor of dopamine-b-hydroxylase | |
| EP0927027A1 (fr) | Utilisation d'antagonistes 5-ht 4? dans la regulation de la secretion de corticosteroides | |
| FR2464071A1 (fr) | Preparation pharmaceutique a base de dihydro-ergotamine et d'heptaminol | |
| AU4743699A (en) | Treating conditions using optically pure (-)-liazrozle | |
| BE825194A (fr) | Hydrazide de n-benzene-sulfonyl-beta-alanine comme agent immunosupressif sur et actif | |
| BE863575A (fr) | Nouvelles compositions pharmaceutiques contenant de la gitoxine comme ingredient actif | |
| AU4743399A (en) | Treating conditions with (+)-liarozole |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RE | Patent lapsed |
Owner name: ADIR Effective date: 19920731 |